Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novel Anticoagulants Need Blood Level Monitoring Measures, FDA’s Temple Says

Executive Summary

Although coagulation level monitoring would negate the newer drugs’ convenience advantage over warfarin, FDA reviews of Daiichi’s Savaysa suggest a tailored dosing approach is needed to optimize antithrombotic benefits against bleeding risks.

You may also be interested in...



Savaysa A-Fib Data Led To Conflicting FDA Views On Dose, Population

Reviewers debated whether to approve Daiichi’s oral anticoagulant only for atrial fibrillation patients with renal impairment or a higher-than-tested dose for those with normal renal function. Disagreements over how to handle renal subgroup efficacy findings also led to differences of opinion on the need for a REMS.

Savaysa A-Fib Data Led To Conflicting FDA Views On Dose, Population

Reviewers debated whether to approve Daiichi’s oral anticoagulant only for atrial fibrillation patients with renal impairment or a higher-than-tested dose for those with normal renal function. Disagreements over how to handle renal subgroup efficacy findings also led to differences of opinion on the need for a REMS.

Savaysa Under-Dosing Not A Concern In DVT/PE Treatment

However, clinical pharmacology and hematology division reviewers differed on whether dose reductions were appropriate for patients of low body weight or using certain concomitant drugs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel